Human monoclonal antibody inhibitor of mannan-binding lectin-associated serine protease-2 (MASP-2)
Trade Name: n/a
Date Designated: 12-16-2013
Orphan Designation: Prevention (inhibition) of complement-mediated thrombotic microangiopathy
Orphan Designation Status: Designated
FDA Orphan Approval Status: Not FDA Approved for Orphan Indication
I just got in last Thursday at 7.40 as a momentum play. Have done a little DD but not much. Almost took my gain today as momentum slowed...glad I didn't and I'm obviously very happy to be holding right now. Based on what little DD I've done, I'm surprised to only see mid-9s in AH. The market potential of MASP-2 insn't massive (AMD, transplants) but is nonetheless nothing to sneeze at. News like this for a lead drug usually packs a bigger punch. Orphan status is a big leg up.
Can anyone be so kind to clarify market potential here and explain why only the small bump? Are there other competitors with better prospects in the pipeline?
Thanks in advance and apologize for not bringing better DD to the table.